drugset
drugset / Trial / NCT00675064

Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects

NCT00675064 ↗

Phase 1 Completed 41 enrolled GlaxoSmithKline Medicines for Malaria Venture · collab
RandomizedParallel-groupSingle-blindOther

Summary

This study will examine safety of single doses of GSK369796 in healthy subjects, along with some test to examine how quickly GSK369796 gets in your blood, and how long it takes your body to get rid of it.

Timeline

Start
2008-05-02
Primary completion
2008-10-12
Completion
2008-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK369796 Small molecule 5 mg Oral
Subject GSK369796 Small molecule 25 mg Oral
Subject GSK369796 Small molecule 100 mg Oral
Subject GSK369796 Small molecule 250 mg Oral
Subject GSK369796 Small molecule 500 mg Oral
Subject GSK369796 Small molecule 1000 mg Oral
Subject GSK369796 Small molecule 2000 mg Oral
Subject GSK369796 Small molecule 3000 mg Oral

Indications

malaria